Contraindicated. Coadministration not recommended; powerful cytochrome P450 enzyme inducers lower systemic publicity to roflumilast and should lessen the therapeutic efficiencyStay away from; coadministration with CYP3A inducers could lead to reduced plasma concentrations of elvitegravir and/or simply a concomitantly administered protease inhibitor